drugset
drugset / Trial / NCT02650479

Study of the Effects of Intravenous Exenatide on Cardiac Repolarization

NCT02650479 ↗

Phase 1 Completed 82 enrolled Intarcia Therapeutics
RandomizedCrossoverQuadruple-blindTreatment

Summary

Two-Part, Randomized, Placebo and Active-Controlled, Double-Blind, Thorough QT Study Evaluating the Effects of Intravenous Exenatide on Cardiac Repolarization in Healthy Male and Female Volunteers

Timeline

Start
2016-01
Primary completion
2016-04
Completion
2016-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Exenatide Peptide 0.0625 ug/kg Intravenous
Subject Moxifloxacin Small molecule 400 mg Oral
Background Palonosetron Other / unclassified 0.25 mg Intravenous

Indications

No indication recorded.